Panagora Asset Management’s Aclaris Therapeutics ACRS Stock Holding History

Panagora Asset Management’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.88M	Buy	502,290 +434,100	+637%	+$1.46M	0.01%	597
2025 Q4	$205K	Buy	68,190 +22,605	+50%	+$57.1K	﹤0.01%	1123
2025 Q3	$86.6K	Buy	+45,585	New	+$79.5K	﹤0.01%	1135
2021 Q3	–	Sell	-749	Closed	-$13K	–	1706
2021 Q2	$13K	Sell	749 -25	-3%	-$568	﹤0.01%	2213
2021 Q1	$20K	Hold	774	–	–	﹤0.01%	2308
2020 Q4	$5K	Buy	+774	New	+$3.27K	﹤0.01%	2444
2020 Q2	–	Sell	-57,155	Closed	-$59K	–	2555
2020 Q1	$59K	Buy	+57,155	New	+$77.8K	﹤0.01%	1847

Other funds holding ACRS

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Panagora Asset Management's ACRS Position: Q1 2026 in Review

Panagora Asset Management increased its Aclaris Therapeutics (ACRS) stake by 637% in Q1 2026, buying an estimated $1.46M and bringing the position to 502,290 shares worth $1.88M. The position accounts for 0.01% of the portfolio, ranked #597.

Panagora Asset Management first reported a position in ACRS in Q1 2020 and has held it in 7 quarters since. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

Panagora Asset Management held 502,290 shares of Aclaris Therapeutics worth $1.88M as of Q1 2026.
Panagora Asset Management bought 434,100 Aclaris Therapeutics shares in Q1 2026, an estimated $1.46M.
Aclaris Therapeutics made up 0.01% of Panagora Asset Management's portfolio in Q1 2026, its #597 holding.
Panagora Asset Management first reported a position in Aclaris Therapeutics in Q1 2020 and has held it in 7 quarters since.
136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Panagora Asset Management's 13F filing for Q1 2026, filed 14 May 2026.